Imprinted and ancient gene: a potential mediator of cancer cell survival during tryptophan deprivation

BackgroundDepletion of tryptophan and the accumulation of tryptophan metabolites mediated by the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1), trigger immune cells to undergo apoptosis. However, cancer cells in the same microenvironment appear not to be affected. Mechanisms whereby cancer cells resist accelerated tryptophan degradation are not completely understood. We hypothesize that cancer cells co-opt IMPACT (the product of IMPrinted and AnCienT gene), to withstand periods of tryptophan deficiency.MethodsA range of bioinformatic techniques including correlation and gene set variation analyses was applied to genomic datasets of cancer (The Cancer Genome Atlas) and normal (Genotype Tissue Expression Project) tissues to investigate IMPACT’s role in cancer. Survival of IMPACT-overexpressing GL261 glioma cells and their wild type counterparts cultured in low tryptophan media was assessed using fluorescence microscopy and MTT bio-reduction assay. Expression of the Integrated Stress Response proteins was measured using Western blotting.ResultsWe found IMPACT to be upregulated and frequently amplified in a broad range of clinical cancers relative to their non-malignant tissue counterparts. In a subset of clinical cancers, high IMPACT expression associated with decreased activity of pathways and genes involved in stress response and with increased activity of translational regulation such as the mTOR pathway. Experimental studies using the GL261 glioma line showed that cells engineered to overexpress IMPACT, gained a survival advantage over wild-type lines when cultured under limiting tryptophan concentrations. No significant difference in the expression of proteins in the Integrated Stress Response pathway was detected in tryptophan-deprived GL261 IMPACT-overexpressors compared to that in wild-type cells. IMPACT-overexpressing GL261 cells but not their wild-type counterparts, showed marked enlargement of their nuclei and cytoplasmic area when stressed by tryptophan deprivation.ConclusionsThe bioinformatics data together with our laboratory studies, support the hypothesis that IMPACT mediates a protective mechanism allowing cancer cells to overcome microenvironmental stresses such as tryptophan deficiency.

[1]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[2]  T. Ito,et al.  Screening for imprinted genes by allelic message display: identification of a paternally expressed gene impact on mouse chromosome 18. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Wallace,et al.  Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. , 1998, Biochemical and biophysical research communications.

[4]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[5]  K. Okamura,et al.  Comparative genome analysis of the mouse imprinted gene impact and its nonimprinted human homolog IMPACT: toward the structural basis for species-specific imprinting. , 2000, Genome research.

[6]  M. Schapira,et al.  Regulated translation initiation controls stress-induced gene expression in mammalian cells. , 2000, Molecular cell.

[7]  D. Munn,et al.  Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division , 2002, Immunology.

[8]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[9]  R. Wek,et al.  Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Hinnebusch,et al.  IMPACT, a Protein Preferentially Expressed in the Mouse Brain, Binds GCN1 and Inhibits GCN2 Activation* , 2005, Journal of Biological Chemistry.

[11]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[12]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.

[13]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[14]  B. Baban,et al.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. , 2007, The Journal of clinical investigation.

[15]  V. Duronio,et al.  Skin cells, but not T cells, are resistant to indoleamine 2, 3‐dioxygenase (IDO) expressed by allogeneic fibroblasts , 2008, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[16]  B. A. Castilho,et al.  Distribution of the protein IMPACT, an inhibitor of GCN2, in the mouse, rat, and marmoset brain , 2008, The Journal of comparative neurology.

[17]  Luis Serrano,et al.  Correlation of mRNA and protein in complex biological samples , 2009, FEBS letters.

[18]  Pedro M. Valero-Mora,et al.  ggplot2: Elegant Graphics for Data Analysis , 2010 .

[19]  A. Ghahary,et al.  High expression of IMPACT protein promotes resistance to indoleamine 2,3‐dioxygenase‐induced cell death , 2010, Journal of cellular physiology.

[20]  C. Piccirillo,et al.  Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives , 2011, Clinical Cancer Research.

[21]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[22]  Sanjeev Gupta,et al.  The eIF2α kinases: their structures and functions , 2013, Cellular and Molecular Life Sciences.

[23]  Hiromitsu Araki,et al.  GeneSetDB: A comprehensive meta-database, statistical and visualisation framework for gene set analysis , 2012, FEBS open bio.

[24]  Ralf Herwig,et al.  The ConsensusPathDB interaction database: 2013 update , 2012, Nucleic Acids Res..

[25]  G. Hajj,et al.  IMPACT Is a Developmentally Regulated Protein in Neurons That Opposes the Eukaryotic Initiation Factor 2α Kinase GCN2 in the modulation of Neurite Outgrowth* , 2013, The Journal of Biological Chemistry.

[26]  J. Renauld,et al.  Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues , 2014, Cancer Immunology Research.

[27]  B. A. Castilho,et al.  Evolutionarily conserved IMPACT impairs various stress responses that require GCN1 for activating the eIF2 kinase GCN2. , 2014, Biochemical and biophysical research communications.

[28]  Richard C. Silva,et al.  Keeping the eIF2 alpha kinase Gcn2 in check. , 2014, Biochimica et biophysica acta.

[29]  D. Amberg,et al.  The Gcn2 Regulator Yih1 Interacts with the Cyclin Dependent Kinase Cdc28 and Promotes Cell Cycle Progression through G2/M in Budding Yeast , 2015, PloS one.

[30]  Sarah Caballero.  Structural and functional characterization of IMPACT proteins: a novel nuclease family , 2016 .

[31]  C. Hopf,et al.  The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas , 2016, Oncoimmunology.

[32]  Richard C. Silva,et al.  Perturbations in actin dynamics reconfigure protein complexes that modulate GCN2 activity and promote an eIF2 response , 2016, Journal of Cell Science.

[33]  R. Strausberg,et al.  Nutritional Stress Induced by Tryptophan-Degrading Enzymes Results in ATF4-Dependent Reprogramming of the Amino Acid Transporter Profile in Tumor Cells. , 2016, Cancer research.

[34]  R. Bast,et al.  Linking genomic reorganization to tumor initiation via the giant cell cycle , 2016, Oncogenesis.

[35]  Mary Goldman,et al.  Toil enables reproducible, open source, big biomedical data analyses , 2017, Nature Biotechnology.